PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer.
暂无分享,去创建一个
[1] J. Copland,et al. Results of a phase 2 trial of ribociclib and letrozole in patients with either relapsed estrogen receptor (ER)-positive ovarian cancers or relapsed ER-positive endometrial cancers. , 2019, Journal of Clinical Oncology.
[2] A. Romano,et al. Anti-estrogen Treatment in Endometrial Cancer: A Systematic Review , 2019, Front. Oncol..
[3] A. Stuckey,et al. A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. , 2018, Gynecologic oncology.
[4] L. Kassem,et al. Targeting mTOR pathway in gynecological malignancies: Biological rationale and systematic review of published data. , 2016, Critical reviews in oncology/hematology.
[5] J. Ledermann,et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer , 2015, International Journal of Gynecologic Cancer.
[6] A. Oza,et al. Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma. , 2015, Journal of Clinical Oncology.
[7] A. Stuckey,et al. A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P. , 2015 .
[8] C. Mathers,et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.
[9] V. Bae-Jump,et al. Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer , 2014, Cancer medicine.
[10] A. Pandiella,et al. Activation of the PI3K/mTOR/AKT Pathway and Survival in Solid Tumors: Systematic Review and Meta-Analysis , 2014, PloS one.
[11] D. Gaffney,et al. Impact of Comorbid Conditions on Survival in Endometrial Cancer , 2014, American journal of clinical oncology.
[12] H. Mackay,et al. Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer , 2014, Cancer.
[13] Steven J. M. Jones,et al. Integrated genomic characterization of endometrial carcinoma , 2013, Nature.
[14] N. Nevadunsky,et al. Pulmonary fibrosis after pegylated liposomal Doxorubicin in a patient with uterine papillary serous carcinoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] H. Burris,et al. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway , 2013, Cancer Chemotherapy and Pharmacology.
[16] R. Coleman,et al. The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer , 2012, Clinical Cancer Research.
[17] Ngai Na Co,et al. Understanding obesity and endometrial cancer risk: opportunities for prevention. , 2011, American journal of obstetrics and gynecology.
[18] J. Sterne,et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.
[19] A. Oza,et al. A randomized phase II (RP2) trial of ridaforolimus (R) compared with progestin (P) or chemotheraphy (C) in female adult patients with advanced endometrial carcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] H. Mackay,et al. Phase II study of oral ridaforolimus in patients with metastatic and/or locally advanced recurrent endometrial cancer: NCIC CTG IND 192. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] C. Mathers,et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.
[22] A. Bryant,et al. Hormonal therapy in advanced or recurrent endometrial cancer. , 2010, The Cochrane database of systematic reviews.
[23] M. Pollak,et al. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells , 2010, Breast Cancer Research and Treatment.
[24] B. Monk,et al. Systemic therapy for recurrent endometrial cancer: a review of North American trials , 2009, Expert review of anticancer therapy.
[25] A. Fader,et al. Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. , 2009, Gynecologic oncology.
[26] J. Ioannidis,et al. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].
[27] H. Andersson,et al. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel— long‐ term follow‐ up , 2008, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
[28] Douglas G. Altman,et al. Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta‐Analysis , 2008 .
[29] A. Jemal,et al. Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.
[30] N. Sonenberg,et al. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. , 2007, Cancer research.
[31] M. Sydes,et al. Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.
[32] J. Green,et al. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review , 2006, International Journal of Gynecologic Cancer.
[33] George L Mutter,et al. Molecular and pathologic aspects of endometrial carcinogenesis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] L. Cantley,et al. Ras, PI(3)K and mTOR signalling controls tumour cell growth , 2006, Nature.
[35] J. Thigpen,et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] E. Jenison,et al. The impact of obesity and age on quality of life in gynecologic surgery. , 2005, American journal of obstetrics and gynecology.
[37] M. Markman. Hormonal therapy of endometrial cancer. , 2005, European journal of cancer.
[38] R. Burger,et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[40] M. Parmar,et al. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.
[41] D. Sackett,et al. Cochrane Collaboration , 1994, BMJ.